Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. J of Skin [Internet]. 2020 Oct. 27 [cited 2025 Apr. 18];4(6):s72. Available from: https://skin.dermsquared.com/skin/article/view/1105